Commercialization of Domestic Cell Therapy Products
First written in FY2017. 3 of 6 entries say "Advanced", first in FY2018-Q2. Latest entry: FY2019-Q1.
No other company in this theme has enough history to compare yet.
- FY2019-Q1AdvancedAnnual report
「The trial was scheduled to continue through the end of fiscal 2019. After safety has been confirmed and proof of concept established, Human Life Code Co., Ltd. plans to conduct a company-sponsored trial of umbilical cord-derived MSCs as a regenerative medicine product and seek regulatory approval.」
Following the start of an investigator-initiated clinical trial at the Institute of Medical Science, the University of Tokyo, ヒューマンライフコード has developed a concrete plan to proceed to company-sponsored clinical trials and regulatory applications for its cell therapy business. - FY2018AdvancedAnnual report
「Last August, ヒューマンライフコード株式会社, which aims to develop domestically produced cell therapies, entered into a license agreement with U.S.-based Tissue Genesis to conduct research, development and sales in Japan and China for a clinical-use stem cell isolation and extraction device covered by Tissue Genesis patents. In September, it entered into a joint research agreement with the Institute of Medical Science, the University of Tokyo, aimed at expanding the indications for umbilical-cord-derived mesenchymal cells to rare diseases in hematologic oncology, where treatment needs remain unmet. In October, it also entered into a joint research agreement with Kansai Medical University on development research aimed at establishing regenerative and reparative treatment for minimally invasive breast reconstruction. Through these and other alliances actively developed during its first year, the company is steadily increasing its business value in the regenerative medicine and cell therapy fields.」
The company made its partnerships and research initiatives in its first year concrete by entering into a license agreement with a U.S. company and joint research agreements with the Institute of Medical Science, the University of Tokyo, and Kansai Medical University. - FY2018-Q3RestatedAnnual report
「In the advanced medical-related business, together with 株式会社ステムセル研究所, ヒューマンライフコード株式会社, which aims to develop domestically produced cell-based pharmaceuticals, and ストレックス株式会社, which manufactures and sells equipment related to regenerative medicine, we are preparing for a listing, centered on the holding company 株式会社トリムメディカル ホールディングス, with the aim of making regenerative medicine and cell therapy one of the pillars of the future Nippon Trim Group.」
The company reaffirmed its policy of making the regenerative medicine and cell therapy businesses, including ステムセル研究所, ヒューマンライフコード and ストレックス, pillars of the Group. - FY2018-Q2AdvancedAnnual report
「ヒューマンライフコード株式会社, established in April, has been actively expanding its operations. In September, it entered into a joint research agreement with the Institute of Medical Science, the University of Tokyo, on umbilical-cord-derived mesenchymal stem cells. In October, it entered into a joint research agreement with Kansai Medical University on development research for equipment to isolate human adipose-derived stem cells for regenerative and reparative treatment for breast reconstruction. The company aims to obtain manufacturing and marketing approval for its first cell therapy product in fiscal 2020.」
ヒューマンライフコード entered into joint research agreements with the Institute of Medical Science, the University of Tokyo, and Kansai Medical University, and explicitly stated its target of obtaining manufacturing and marketing approval for its first cell therapy product in fiscal 2020. - FY2018-Q1RestatedAnnual report
「In the healthcare-related business, we established 「ヒューマンライフコード株式会社」 in April to develop domestically produced cell therapies, and in May entered into a capital partnership with 「ストレックス株式会社」, which manufactures and sells medical equipment. We are strengthening our structure to make advanced medicine a core business of the 日本トリム Group in the future.」
The company reaffirmed its efforts to strengthen its structure centered on advanced medicine, based on the establishment of ヒューマンライフコード and the capital partnership with ストレックス. - FY2017First statedAnnual report
「In April, we established a new company, 「ヒューマンライフコード株式会社」, with the aim of developing pharmaceutical products from cells derived from human tissues such as the placenta and umbilical cord. Through strategic partnerships with companies in Japan and the United States, we will establish a system capable of providing a stable supply of high-quality, safe, domestically produced cell therapies and work to industrialize cell therapy.」
The company established a new company to develop pharmaceutical products from cells derived from human tissues and aims to build a supply system for domestically produced cell therapies through partnerships with companies in Japan and the United States.